Interdisciplinary education to integrate pathology and epidemiology: Towards molecular and population-level health science

American Journal of Epidemiology

Volumn 176, Issue 8, 2012, Pages 659-667

  Ogino, Shuji ^a,b,c,d   King, Emily E ^b   Beck, Andrew H ^a,e   Sherman, Mark E ^f   Milner, Danny A ^b,c   Giovannucci, Edward ^a,b,c  

^a DANA FARBER HARVARD CANCER CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

education, public health professional; health care reform; individualized medicine; interdisciplinary communication; molecular epidemiology; pathology

Indexed keywords

CANCER; CARDIOVASCULAR DISEASE; CURRICULUM; DIABETES; EDUCATIONAL DEVELOPMENT; EPIDEMIOLOGY; HEALTH EDUCATION; HEALTH POLICY; HEALTH WORKER; INFECTIOUS DISEASE; INTEGRATED APPROACH; INTERDISCIPLINARY APPROACH; MOLECULAR ANALYSIS; PATHOLOGY; PROTEOMICS; PUBLIC HEALTH; STUDENT;

ARTICLE; CHRONIC DISEASE; EDUCATION; HEALTH CARE POLICY; HEALTH EDUCATION; HEALTH SCIENCE; INTERDISCIPLINARY COMMUNICATION; INTERDISCIPLINARY EDUCATION; MEDICAL EDUCATION; MEDICAL SCHOOL; MOLECULAR EPIDEMIOLOGY; MOLECULAR PATHOLOGY; NEOPLASM; PERSONALIZED MEDICINE; POSTGRADUATE EDUCATION; PUBLIC HEALTH; SCHOOL;

CHRONIC DISEASE; EPIDEMIOLOGY; HEALTH PROMOTION; HUMANS; INTERDISCIPLINARY COMMUNICATION; MODELS, EDUCATIONAL; NEOPLASMS; PATHOLOGY; PUBLIC HEALTH; UNITED STATES;

EID: 84864613664     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kws226     Document Type: Article

References (86)

1. Alberts B. Getting education right [editorial]. Science. 2011;333(6045):919.
2. Sharp PA, Langer R. Research agenda. Promoting convergence in biomedical science. Science. 2011; 333(6042):527.
3. Smith GD. Epidemiology, epigenetics and the 'Gloomy Prospect': embracing randomness in population health research and practice. Int J Epidemiol. 2011;40(3):537-562.
4. Ogino S, Stampfer M. Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology. J Natl Cancer Inst. 2010;102(6):365-367.
5. Ogino S, Galon J, Fuchs CS, et al. Cancer immunology-analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol. 2011;8(12):711-719.
6. Ogino S, Chan AT, Fuchs CS, et al. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut. 2011; 60(3):397-411.
7. Wuchty S, Jones BF, Uzzi B. The increasing dominance of teams in production of knowledge. Science. 2007; 316(5827):1036-1039.
8. Rebbeck TR, Paskett E, Sellers TA. Fostering transdisciplinary science. Cancer Epidemiol Biomarkers Prev. 2010;19(5):1149-1150.
9. Stokols D, Hall KL, Taylor BK, et al. The science of team science: overview of the field and introduction to the supplement. Am J Prev Med. 2008;35(2 suppl):S77-S89.
10. Sellers TA, Caporaso N, Lapidus S, et al. Opportunities and barriers in the age of team science: strategies for success. Cancer Causes Control. 2006;17(3):229-237.
11. Sherman ME, Howatt W, Blows FM, et al. Molecular pathology in epidemiologic studies: a primer on key considerations. Cancer Epidemiol Biomarkers Prev. 2010;19(4):966-972.
12. Wade A. Fear or favour? Statistics in pathology. J Clin Pathol. 2000;53(1):16-18.
13. Ioannidis JP. Why most published research findings are false. PLoS Med. 2005;2(8):e124. (doi:10.1371/journal.pmed. 0020124).
14. McShane LM, Altman DG, Sauerbrei W. Identification of clinically useful cancer prognostic factors: what are we missing? J Natl Cancer Inst. 2005;97(14):1023-1025.
15. Kohane IS, Masys DR, Altman RB. The incidentalome: a threat to genomic medicine. JAMA. 2006;296(2):212-215.
16. Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4(10):e297. (doi:10.1371/journal.pmed.0040297).
17. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4(10):e296. (doi:10.1371/ journal. pmed.0040296).
18. Ogino S, Goel A. Molecular classification and correlates in colorectal cancer. J Mol Diagn. 2008;10(1):13-27.
19. Curtin K, Slattery ML, Samowitz WS. CpG island methylation in colorectal cancer: past, present and future. Pathol Res Int. 2011;2011:902674. (doi:10.4061/2011/902674).
20. Hughes LA, Simons CC, van den Brandt PA, et al. Body size, physical activity and risk of colorectal cancer with or without the CpG island methylator phenotype (CIMP). PLoS One. 2011;6(4):e18571. (doi:10.1371/journal.pone. 0018571).
21. Boyle T, Fritschi L, Heyworth J, et al. Long-term sedentary work and the risk of subsite-specific colorectal cancer. Am J Epidemiol. 2011;173(10):1183- 1191.
22. Kelley RK, Wang G, Venook AP. Biomarker use in colorectal cancer therapy. J Natl Compr Canc Netw. 2011; 9(11):1293-1302.
23. Chen D, Song S, Lu J, et al. Functional variants of-1318T > G and-673C > T in c-Jun promoter region associated with increased colorectal cancer risk by elevating promoter activity. Carcinogenesis. 2011; 32(7):1043-1049.
24. Campbell PT, Newton CC, Dehal AN, et al. Impact of body mass index on survival after colorectal cancer diagnosis: the Cancer Prevention Study-II Nutrition Cohort. J Clin Oncol. 2012;30(1):42-52.
25. Boyle T, Heyworth J, Bull F, et al. Timing and intensity of recreational physical activity and the risk of subsite-specific colorectal cancer. Cancer Causes Control. 2011;22(12): 1647-1658.
26. Gehoff A, Basten O, Sprenger T, et al. Optimal lymph node harvest in rectal cancer (UICC stages II and III) after preoperative 5-FU-based radiochemotherapy. Acetone compression is a new and highly efficient method. Am J Surg Pathol. 2012;36(2):202-213.
27. Hughes LA, Khalid-de Bakker CA, Smits KM, et al. The CpG island methylator phenotype in colorectal cancer: progress and problems. Biochim Biophys Acta. 2012; 1825(1):77-85.
28. Iwagami S, Baba Y, Watanabe M, et al. Pyrosequencing assay to measure LINE-1 methylation level in esophageal squamous cell carcinoma. Ann Surg Oncol. 2012;19(8): 2726-2732.
29. Esteban S, Moya P, Fernandez-Suarez A, et al. Diagnostic and prognostic utility of methylation and protein expression patterns of myopodin in colon cancer. Tumour Biol. 2012; 33(2):337-346.
30. Begg CB. A strategy for distinguishing optimal cancer subtypes. Int J Cancer. 2011;129(4):931-937.
31. Chen H, Taylor NP, Sotamaa KM, et al. Evidence for heritable predisposition to epigenetic silencing of MLH1. Int J Cancer. 2007;120(8):1684-1688.
32. Raptis S, Mrkonjic M, Green RC, et al. MLH1-93G>A promoter polymorphism and the risk of microsatelliteunstable colorectal cancer. J Natl Cancer Inst. 2007; 99(6):463-474.
33. Samowitz WS, Curtin K, Wolff RK, et al. The MLH1-93 G>A promoter polymorphism and genetic and epigenetic alterations in colon cancer. Genes Chromosomes Cancer. 2008;47(10):835-844.
34. Allan JM, Shorto J, Adlard J, et al. MLH1-93G>A promoter polymorphism and risk of mismatch repair deficient colorectal cancer. Int J Cancer. 2008;123(10):2456-2459.
35. Campbell PT, Curtin K, Ulrich CM, et al. Mismatch repair polymorphisms and risk of colon cancer, tumour microsatellite instability and interactions with lifestyle factors. Gut. 2009;58(5):661-667.
36. Oyama K, Kawakami K, Maeda K, et al. The association between methylenetetrahydrofolate reductase polymorphism and promoter methylation in proximal colon cancer. Anticancer Res. 2004;24(2B):649-654.
37. Curtin K, Slattery ML, Ulrich CM, et al. Genetic polymorphisms in one-carbon metabolism: associations with CpG island methylator phenotype (CIMP) in colon cancer and the modifying effects of diet. Carcinogenesis. 2007; 28(8):1672-1679.
38. Jensen LH, Lindebjerg J, Cruger DG, et al. Microsatellite instability and the association with plasma homocysteine and thymidylate synthase in colorectal cancer. Cancer Invest. 2008;26(6):583-589.
39. de Vogel S, Wouters KA, Gottschalk RW, et al. Genetic variants of methyl metabolizing enzymes and epigenetic regulators: associations with promoter CpG island hypermethylation in colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2009;18(11):3086-3096.
40. Schernhammer ES, Giovannucci E, Kawasaki T, et al. Dietary folate, alcohol, and B vitamins in relation to LINE-1 hypomethylation in colon cancer. Gut. 2010;59(6):794-799.
41. Hazra A, Fuchs CS, Kawasaki T, et al. Germline polymorphisms in the one-carbon metabolism pathway and DNA methylation in colorectal cancer. Cancer Causes Control. 2010;21(3):331-345.
42. Van Guelpen B, Dahlin AM, Hultdin J, et al. One-carbon metabolism and CpG island methylator phenotype status in incident colorectal cancer: a nested case-referent study. Cancer Causes Control. 2010;21(4):557-566.
43. Curtin K, Samowitz WS, Ulrich CM, et al. Nutrients in folate-mediated, one-carbon metabolism and the risk of rectal tumors in men and women. Nutr Cancer. 2011;63(3): 357-366.
44. Ogino S, Hazra A, Tranah GJ, et al. MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer. Carcinogenesis. 2007;28(9):1985-1990.
45. Hawkins NJ, Lee JH, Wong JJ, et al. MGMT methylation is associated primarily with the germline C>T SNP (rs16906252) in colorectal cancer and normal colonic mucosa. Mod Pathol. 2009;22(12):1588-1599.
46. Candiloro IL, Dobrovic A. Detection of MGMT promoter methylation in normal individuals is strongly associated with the T allele of the rs16906252 MGMT promoter single nucleotide polymorphism. Cancer Prev Res (Phila Pa). 2009;2(10):862-867.
47. Leng S, Bernauer AM, Hong C, et al. The A/G allele of Rs16906252 predicts for MGMT methylation and is selectively silenced in premalignant lesions from smokers and in lung adenocarcinomas. Clin Cancer Res. 2011;17(7): 2014-2023.
48. Kristensen LS, Nielsen HM, Hager H, et al. Methylation of MGMT in malignant pleural mesothelioma occurs in a subset of patients and is associated with the T allele of the rs16906252 MGMT promoter SNP. Lung Cancer. 2011; 71(2):130-136.
49. Pedroni M, Tamassia MG, Percesepe A, et al. Microsatellite instability in multiple colorectal tumors. Int J Cancer. 1999;81(1):1-5.
50. Velayos FS, Lee SH, Qiu H, et al. The mechanism of microsatellite instability is different in synchronous and metachronous colorectal cancer. J Gastrointest Surg. 2005; 9(3):329-335.
51. Nosho K, Kure S, Irahara N, et al. A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers. Gastroenterology. 2009; 137(5):1609-1620.e1-3.
52. Konishi K, Shen L, Jelinek J, et al. Concordant DNA methylation in synchronous colorectal carcinomas. Cancer Prev Res (Phila Pa). 2009;2(9):814-822.
53. Gonzalo V, Lozano JJ, Muñoz J, et al. Aberrant gene promoter methylation associated with sporadic multiple colorectal cancer. PLoS One. 2010;5(1):e8777. (doi:10.1371/journal.pone.0008777).
54. Slattery ML, Curtin K, Anderson K, et al. Associations between cigarette smoking, lifestyle factors, and microsatellite instability in colon tumors. J Natl Cancer Inst. 2000;92(22): 1831-1836.
55. Satia JA, Keku T, Galanko JA, et al. Diet, lifestyle, and genomic instability in the North Carolina colon cancer study. Cancer Epidemiol Biomarkers Prev. 2005;14(2): 429-436.
56. Slattery ML, Curtin K, Sweeney C, et al. Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer. Int J Cancer. 2007;120(3): 656-663.
57. Campbell PT, Jacobs ET, Ulrich CM, et al. Case-control study of overweight, obesity, and colorectal cancer risk, overall and by tumor microsatellite instability status. J Natl Cancer Inst. 2010;102(6):391-400.
58. Sinicrope FA, Foster NR, Sargent DJ, et al. Obesity is an independent prognostic variable in colon cancer survivors. Clin Cancer Res. 2010;16(6):1884-1893.
59. Kuchiba A, Morikawa T, Yamauchi M, et al. Body mass index and risk of colorectal cancer according to fatty acid synthase expression in the Nurses' Health Study. J Natl Cancer Inst. 2012;104(5):415-420.
60. Wu AH, Shibata D, Yu MC, et al. Dietary heterocyclic amines and microsatellite instability in colon adenocarcinomas. Carcinogenesis. 2001;22(10):1681-1684.
61. Lüchtenborg M, Weijenberg MP, Kampman E, et al. Cigarette smoking and colorectal cancer: APC mutations, hMLH1 expression, and GSTM1 and GSTT1 polymorphisms. Am J Epidemiol. 2005;161(9):806-815.
62. Chia VM, Newcomb PA, Bigler J, et al. Risk of microsatellite-unstable colorectal cancer is associated jointly with smoking and nonsteroidal anti-inflammatory drug use. Cancer Res. 2006;66(13):6877-6883.
63. Samowitz WS, Albertsen H, Sweeney C, et al. Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. J Natl Cancer Inst. 2006;98(23):1731-1738.
64. Poynter JN, Haile RW, Siegmund KD, et al. Associations between smoking, alcohol consumption, and colorectal cancer, overall and by tumor microsatellite instability status. Cancer Epidemiol Biomarkers Prev. 2009; 18(10):2745-2750.
65. Rozek LS, Herron CM, Greenson JK, et al. Smoking, gender, and ethnicity predict somatic BRAF mutations in colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2010; 19(3):838-843.
66. Limsui D, Vierkant RA, Tillmans LS, et al. Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. J Natl Cancer Inst. 2010;102(14):1012-1022.
67. Ogino S, Nosho K, Meyerhardt JA, et al. Cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol. 2008;26(35):5713-5720.
68. Ogino S, Nosho K, Shima K, et al. p21 expression in colon cancer and modifying effects of patient age and body mass index on prognosis. Cancer Epidemiol Biomarkers Prev. 2009;18(9):2513-2521.
69. Ogino S, Shima K, Nosho K, et al. A cohort study of p27 localization in colon cancer, body mass index, and patient survival. Cancer Epidemiol Biomarkers Prev. 2009;18(6): 1849-1858.
70. Ogino S, Nosho K, Baba Y, et al. A cohort study of STMN1 expression in colorectal cancer: body mass index and prognosis. Am J Gastroenterol. 2009;104(8): 2047-2056.
71. Meyerhardt JA, Ogino S, Kirkner GJ, et al. Interaction of molecular markers and physical activity on mortality in patients with colon cancer. Clin Cancer Res. 2009;15(18): 5931-5936.
72. Morikawa T, Kuchiba A, Yamauchi M, et al. Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. JAMA. 2011;305(16):1685-1694.
73. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA. 2009;302(6):649-658.
74. Morikawa T, Kuchiba A, Liao X, et al. Tumor TP53 expression status, body mass index and prognosis in colorectal cancer. Int J Cancer. 2012;131(5):1169-1178.
75. Ebrahim S, Clarke M. STROBE: new standards for reporting observational epidemiology, a chance to improve. Int J Epidemiol. 2007;36(5):946-948.
76. Gallo V, Egger M, McCormack V, et al. STrengthening the Reporting of OBservational studies in Epidemiology-Molecular Epidemiology (STROBE-ME): an extension of the STROBE statement. PLoS Med. 2011;8(10):e1001117. (doi:10.1371/journal.pmed.1001117).
77. Stein RA. Epigenetics-the link between infectious diseases and cancer. JAMA. 2011;305(14):1484-1485.
78. Nosho K, Shima K, Kure S, et al. JC virus T-antigen in colorectal cancer is associated with p53 expression and chromosomal instability, independent of CpG island methylator phenotype. Neoplasia. 2009;11(1):87-95.
79. Karpinski P, Myszka A, Ramsey D, et al. Detection of viral DNA sequences in sporadic colorectal cancers in relation to CpG island methylation and methylator phenotype. Tumour Biol. 2011;32(4):653-659.
80. Yamauchi M, Morikawa T, Kuchiba A, et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut. 2012;61(6): 847-854.
81. Yamauchi M, Lochhead P, Morikawa T, et al. Colorectal cancer: a tale of two sides or a continuum? Gut. 2012;61(6): 794-797.
82. Baba Y, Nosho K, Shima K, et al. PTGER2 overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype. Cancer Epidemiol Biomarkers Prev. 2010;19(3):822-831.
83. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883-899.
84. Wang D, Xia D, DuBois RN. The crosstalk of PTGS2 and EGF signaling pathways in colorectal cancer. Cancers. 2011;3(4):3894-3908.
85. Xia D, Wang D, Kim SH, et al. Prostaglandin E2 promotes intestinal tumor growth via DNA methylation. Nat Med. 2012;18(2):224-226.
86. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med. 2007;356(21):2131-2142.